Hematologic Oncology | Specialty

Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

November 6th 2020

Dr. Braunschweig on Mitigating the Toxicities of CAR T-Cell Therapy in Lymphoma

November 5th 2020

Ira Braunschweig, MD, discusses mitigating ​the toxicities that are associated with CAR T-cell therapy in lymphoma.

EU Approval Sought for Subcutaneous Daratumumab in Light-Chain Amyloidosis

November 5th 2020

A Type II variation application has been submitted by Janssen Pharmaceutica NV to the European Medicines Agency for the subcutaneous formulation of daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone for use in adult patients with light-chain amyloidosis.

Dr. Pemmaraju on a New Era of Treatment Strategies in BPDCN

November 4th 2020

Naveen Pemmaraju, MD, discusses current treatment strategies in blastic plasmacytoid dendritic cell neoplasm.

BCMA-Targeting Drugs Take Center Stage in Myeloma

November 4th 2020

The treatment landscape for multiple myeloma is poised to enter a new era of innovation with the development of therapies that target B-cell maturation antigen, which is highly expressed on plasma and MM cells.

Dr. Schiffer on Factors to Consider for TKI Discontinuation in CML

November 2nd 2020

Charles Schiffer, MD, discusses factors to consider for TKI discontinuation in chronic myeloid leukemia.

Standardizing Optimal Diagnostic Procedures and Monitoring Strategies in CML

October 29th 2020

During the 2020 Institutional Perspectives in Cancer webinar on hematologic malignancies, Sudipto Mukherjee, MD, PhD, MPH, provides detail as to some of these nuances and the optimal management of patients with CML.

Beat AML Master Clinical Trial Showcases Paradigm Shift With Precision Medicine

October 28th 2020

Delaying treatment for up to 7 days so that genomic data can be utilized to inform a personalized treatment approach is safe, feasible, and can improve overall survival in patients with acute myeloid leukemia.

Schiffer Spotlights Potential for TKI Discontinuation in Select Patients With CML

October 28th 2020

Charles Schiffer, MD, discusses integration of TKIs, such as imatinib, into the chronic myeloid leukemia treatment paradigm.

Cellular Therapies Move Forward in Lymphomas and Leukemias, But Challenges Remain

October 27th 2020

Abhinav Deol, MD, highlights the progress that has been made with CAR T-cell therapy in leukemia and lymphoma, challenges faced with regard to accessibility and toxicity, and next steps for this modality.

Dr. Jacobson on the Significance of CD19-Targeted CAR T-Cell Therapy in B-Cell Malignancies

October 27th 2020

Caron Jacobson, MD, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.

Cellular and Targeted Therapies Push the Envelope in Hematologic Malignancies

October 27th 2020

Jeffrey Zonder, MD, discusses the explosion of targeted therapies, along with the rise of cellular therapy, in hematologic malignancies.

Dr. Galligan on Unmet Needs in High-Risk Multiple Myeloma

October 27th 2020

Derek C. Galligan, MD, discusses unmet needs in high-risk multiple myeloma.

FDA Approval Insights: Selinexor in Relapsed/Refractory DLBCL

October 26th 2020

In our exclusive interview, Brian T. Hill, MD, PhD, provides perspective on the FDA approval of selinexor in relapsed/refractory diffuse large B-cell lymphoma.

Maintenance Daratumumab Improves PFS in Newly Diagnosed Transplant-Eligible Myeloma

October 22nd 2020

Single-agent daratumumab as maintenance therapy improved progression-free survival compared with observation in patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant.

Novel Strategies for Targeting the “Guardian of the Genome” Emerge

October 22nd 2020

p53 presents a significant challenge for investigators, and the field is littered with clinical trial failures and abandoned drug development programs.

FDA Grants Full Approval to Venetoclax Combo in Newly Diagnosed AML

October 16th 2020

The FDA has granted regular approval to venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine for patients with newly diagnosed acute myeloid leukemia who are 75 years or older or who have comorbidities precluding intensive induction chemotherapy.

Garcia-Manero Previews Potential Therapeutic Standards in TP53-Mutated MDS/AML

October 15th 2020

In our exclusive interview, Guillermo Garcia-Manero, MD, discusses the prevalence of TP53 mutations in myelodysplastic syndromes and acute myeloid leukemia, the prognosis these mutations confer, and the development of eprenetapopt and magrolimab in this patient population.

Guadecitabine Fails to Significantly Improve OS in Previously Treated AML and MDS/CMML

October 15th 2020

Guadecitabine failed to result in a statistically significant improvement in overall survival compared with physician’s choice of alternative therapy in previously treated adult patients with acute myeloid leukemia and myelodysplastic syndromes or chronic myelomonocytic leukemia.

HDAC/mTOR Inhibitor Combos Exhibit Activity in Relapsed/Refractory Hodgkin Lymphoma

October 15th 2020

The addition of the histone deacetylase inhibitor vorinostat to the mTOR inhibitors sirolimus or everolimus demonstrated encouraging clinical activity and manageable safety in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.